SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

October 8, 2026

SOPHiA GENETICS and Myriad Genetics, Inc. have announced a collaboration aimed at advancing a new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology initiatives with AstraZeneca. PrGIS is designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients, with the goal of enhancing clinical trials and improving access to precision oncology medicines through potential companion diagnostic solutions.

Myriad developed PrGIS to function as an actionable biomarker in prostate cancer, where HRD is becoming recognized as an important prognostic and predictive indicator. The proprietary MyChoice® CDx test, currently available as a companion diagnostic in ovarian cancer, will generate the PrGIS score and is now being developed for prostate cancer as a new indication.

"This collaboration showcases Myriad's biopharma capabilities to support development of precision oncology treatments," said Lou Welebob, Senior Vice President, Companion Diagnostics at Myriad Genetics. "PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies."

As part of this partnership, SOPHiA GENETICS is creating a decentralized companion diagnostic solution that incorporates Myriad's PrGIS technology. This solution aims to increase patient access to PrGIS across global markets. SOPHiA GENETICS' technology-agnostic, cloud-based platform facilitates local laboratory testing through a network of over 1,000 connected institutions in more than 75 countries.

Jess Lambe, VP & Managing Director of BioPharma Business Development at SOPHiA GENETICS, emphasized the geographical challenges in precision medicine: "Breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world. By pairing Myriad's world-class biomarker innovation with SOPHiA GENETICS' global network, we are working toward a solution for this."

Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026, which is expected to further characterize the biomarker and support its validation. Full details will be available following the ESMO embargo period.

Share
Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.